This application entitled """"""""Targeting multiple diseases through gamma -secretase"""""""" will evaluate the use of gamma -secretase inhibitors to target CNS disease, inflammatory responses and carcinogenesis. The molecular target that forms the focus of this study, gamma -secretase, has been the subject of intense investigation by the academic and industrial communities for its importance in the pathogenesis of Alzheimer's disease (AD). Gamma-secretase has several targets including the Notch family of proteins. Therefore inhibition of gamma -secretase is likely to have broad effects on cellular physiology. Several classes of drugs have been developed which inhibit gamma -secretase with variable potency and specificity. Based on preliminary data presented in this application, we suggest that targeting gamma -secretase is likely to have bread ranging effects in the CNS, immune system as well as in developing tumors and pose experiments to test these predictions. In Project 1, we will develop biomarkers to evaluate the effect of gamma -secretase inhibition on Notch and correlate these data with reduction in the A-beta fragment of amyloid precursor protein. The role of Notch signaling in demyelination also will be studied. In Project 2, the effects of gamma -secretase inhibition will be studied in a variety of in vivo immune responses including immune response to two pathogens, antibody production and autoimmunity. In Project 3, we will determine the effect of gamma -secretase inhibition on the maintenance of the neoplastic phenotype. Overall this Program describes an interdisciplinary approach directed at establishing the efficacy of targeting an enzymatic activity, gamma -secretase in multiple disease models.
| Ran, Yong; Cruz, Pedro E; Ladd, Thomas B et al. (2014) ?-Secretase processing and effects of ?-secretase inhibitors and modulators on long A? peptides in cells. J Biol Chem 289:3276-87 |
| Zhang, Shubing; Chung, Wen-cheng; Miele, Lucio et al. (2014) Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer. Cancer Biol Ther 15:633-42 |
| Roderick, Justine E; Gonzalez-Perez, Gabriela; Kuksin, Christina Arieta et al. (2013) Therapeutic targeting of NOTCH signaling ameliorates immune-mediated bone marrow failure of aplastic anemia. J Exp Med 210:1311-29 |
| Espinoza, Ingrid; Miele, Lucio (2013) Notch inhibitors for cancer treatment. Pharmacol Ther 139:95-110 |
| Golde, Todd E; Koo, Edward H; Felsenstein, Kevin M et al. (2013) ?-Secretase inhibitors and modulators. Biochim Biophys Acta 1828:2898-907 |
| Espinoza, Ingrid; Miele, Lucio (2013) Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells. Cancer Lett 341:41-5 |
| Chakrabarty, Paramita; Tianbai, Li; Herring, Amanda et al. (2012) Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol Neurodegener 7:36 |
| Das, Pritam; Verbeeck, Christophe; Minter, Lisa et al. (2012) Transient pharmacologic lowering of Aýý production prior to deposition results in sustained reduction of amyloid plaque pathology. Mol Neurodegener 7:39 |
| Minter, Lisa M; Osborne, Barbara A (2012) Canonical and non-canonical Notch signaling in CD4? T cells. Curr Top Microbiol Immunol 360:99-114 |
| Cho, Sungpil; Lu, Meiling; He, Xiaolong et al. (2011) Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proc Natl Acad Sci U S A 108:20778-83 |
Showing the most recent 10 out of 32 publications
